1st Quarter - Report — CEPHEID for CEPHEID (2017)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$12,300

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
1st Quarter - Termination	May 11, 2017	$25,000	Replaced
1st Quarter - Report (this page)	May 11, 2017	$12,300	Replaced
1st Quarter - Termination Amendment	Mar 23, 2018	$12,300	Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

IVD regulation reform, antimicrobial resistance policies, CMS coverage and ;payment issues

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Disease Control & Prevention (CDC); White House Office; HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Veterans Affairs, Dept of (VA); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

CMS coverage determination process, delay in PAMA implementation

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); SENATE; Agency for Healthcare Research & Quality (AHRQ); White House Office; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

IVD regulatory reform, CMS coverage determination process

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Health & Human Services, Dept of (HHS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA)

Science/Technology SCI

IVD regulatory reform, point of care testing

Lobbyist	Covered position, as disclosed
MICHELE M SCHOONMAKER	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Centers For Disease Control & Prevention (CDC); White House Office; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.